2,6-Dichlorophenol

2,6-Dichlorophenol

SCHEMBL949095

Oc1c(Cl)cccc1Cl.[NaH]

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.52
ALDH1A1 P00352 6/20 0.50
CYP1A2 P05177 3/20 0.47
CYP2A6 P11509 2/20 0.47
LMNA P02545 2/20 0.47
HSD17B10 Q99714 4/20 0.45
RECQL P46063 2/20 0.45
TTR P02766 1/20 0.45
CYP3A4 P08684 1/20 0.45
HSP90AA1 P07900 1/20 0.45
IDO1 P14902 1/20 0.43
ALOX15 P16050 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
ADAMTS4 O75173 1/20 0.42
EGFR P00533 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
FYN P06241 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2,6-Dichlorophenol SCHEMBL65234 0.97
2,6-Dichlorophenol SCHEMBL10747747 0.93 TSHR (0.52) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL30790427 0.93 TSHR (0.52) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL30257485 0.93 TSHR (0.52) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL8986495 0.90 TSHR (0.50) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL28437484 0.85 ALDH1A1 (0.65) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL5578255 0.83 ALDH1A1 (0.44) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL28670279 0.83 CA12 (0.58) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL5010979 0.83 TSHR (0.44) TSHRALDH1A1CYP1A2CYP2A6LMNA
2,6-Dichlorophenol SCHEMBL28241861 0.83 ALDH1A1 (0.50) TSHRALDH1A1CYP1A2CYP2A6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4136075-B1 PROCESS FOR THE SYNTHESIS OF LOFEXIDINE MEDICHEM SA (ES) 2024-06-05 EP disclosed
CN-117831658-A Urine analysis model generation method, urine analysis method and urine analysis system 杉木(深圳)生物科技有限公司 2024-04-05 CN disclosed
CN-107986387-B Ultrasound-assisted selective photocatalysis method and device based on magnetic molecular imprinting 长安大学 2023-09-22 CN disclosed
CN-113429308-B Synthesis process of diclofenac sodium 安徽普利药业有限公司 2023-07-18 CN disclosed
CN-113429308-B Synthesis process of diclofenac sodium 安徽普利药业有限公司 2023-07-18 CN disclosed
US-20230123335-A1 PROCESS FOR THE SYNTHESIS OF LOFEXIDINE MEDICHEM, S.A. (ES) 2023-04-20 US disclosed
EP-4136075-A1 PROCESS FOR THE SYNTHESIS OF LOFEXIDINE Medichem, S.A. (ES) 2023-02-22 EP disclosed
WO-2021209617-A1 PROCESS FOR THE SYNTHESIS OF LOFEXIDINE MEDICHEM, S.A. (ES) 2021-10-21 WO disclosed
CN-113429308-A Process for synthesizing diclofenac sodium 安徽普利药业有限公司 2021-09-24 CN disclosed
CN-113429308-A Process for synthesizing diclofenac sodium 安徽普利药业有限公司 2021-09-24 CN disclosed
US-20130087298-A1 Sensor Wipe For Detecting Surface Conditions KIMBERLY-CLARK WORLDWIDE, INC. 2013-04-11 US disclosed
EP-2334297-A1 LOFEXIDINE ENANTIOMERS FOR USE AS A TREATMENT FOR CNS DISEASE AND PATHOLOGIES AND ITS CHIRAL SYNTHESIS Agean Llc (US) 2011-06-22 EP disclosed
US-20110015246-A2 LOFEXIDINE ENANTIOMERS FOR USE AS A TREATMENT FOR CNS DISEASE AND PATHOLOGIES AND ITS CHIRAL SYNTHESIS AGEAN LLC (US) 2011-01-20 US disclosed
WO-2010016844-A1 LOFEXIDINE ENANTIOMERS FOR USE AS A TREATMENT FOR CNS DISEASE AND PATHOLOGIES AND ITS CHIRAL SYNTHESIS AGEAN LLC (US) 2010-02-11 WO disclosed
US-20080319041-A1 Lofexidine enantiomers for use as a treatment for CNS disease and pathologies and its chiral synthesis AGEAN LLC 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319041-A1 Lofexidine enantiomers for use as a treatment for CNS disease and pathologies and its chiral synthesis CYP2C9, CCR9, PNMT TSHR 2445/4885ALDH1A1 1426/4885CYP1A2 35/4885
US-20230123335-A1 PROCESS FOR THE SYNTHESIS OF LOFEXIDINE LPXN, LOX, LCT TSHR 1842/4885ALDH1A1 831/4885CYP1A2 172/4885
US-20110015246-A2 LOFEXIDINE ENANTIOMERS FOR USE AS A TREATMENT FOR CNS DISEASE AND PATHOLOGIES AND ITS CHIRAL SYNTHESIS CYP2C9, CCR9, PNMT TSHR 2445/4885ALDH1A1 1426/4885CYP1A2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.